Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Rix

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
ACS Chemical Biology|May 31, 2017
Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer ActivityGabriela Wright, Volha Golubeva, Lily L Remsing Rix, et al.
ACS Chemical Biology|November 13, 2013
GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cellsLily L Remsing Rix, Brent M Kuenzi, Yunting Luo, et al.
Journal of the American Chemical Society|May 8, 2003
Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesisLily L Remsing, Ana M González, Mohammad Nur-e-Alam, et al.
Molecular Cancer Therapeutics|July 20, 2011
An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and BGeorg E Winter, Uwe Rix, Andrej Lissat, et al.
Cancer Research|October 29, 2014
Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutationsYun Bai, Jae-Young Kim, January M Watters, et al.
Molecular & Cellular Proteomics : MCP|September 16, 2018
Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer CellsClaudia Ctortecka, Vinayak Palve, Brent M Kuenzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2021
Cell Type-specific Adaptive Signaling Responses to KRAS<sup>G12C</sup> InhibitionHitendra S Solanki, Eric A Welsh, Bin Fang, et al.
Chemistry & Biology|May 5, 2004
Generation of new landomycins by combinatorial biosynthetic manipulation of the LndGT4 gene of the landomycin E cluster in S. globisporusBohdan Ostash, Uwe Rix, Lily L Remsing Rix, et al.
FEBS Open Bio|July 18, 2019
Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 modelBhaswati Sarcar, Nicholas T Gimbrone, Gabriela Wright, et al.
Plos One|October 17, 2013
A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALLUwe Rix, Jacques Colinge, Katharina Blatt, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
ACS Chemical Biology|May 31, 2017
Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer ActivityGabriela Wright, Volha Golubeva, Lily L Remsing Rix, et al.
ACS Chemical Biology|November 13, 2013
GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cellsLily L Remsing Rix, Brent M Kuenzi, Yunting Luo, et al.
Journal of the American Chemical Society|May 8, 2003
Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesisLily L Remsing, Ana M González, Mohammad Nur-e-Alam, et al.
Molecular Cancer Therapeutics|July 20, 2011
An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and BGeorg E Winter, Uwe Rix, Andrej Lissat, et al.
Cancer Research|October 29, 2014
Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutationsYun Bai, Jae-Young Kim, January M Watters, et al.
Molecular & Cellular Proteomics : MCP|September 16, 2018
Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer CellsClaudia Ctortecka, Vinayak Palve, Brent M Kuenzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2021
Cell Type-specific Adaptive Signaling Responses to KRAS<sup>G12C</sup> InhibitionHitendra S Solanki, Eric A Welsh, Bin Fang, et al.
Chemistry & Biology|May 5, 2004
Generation of new landomycins by combinatorial biosynthetic manipulation of the LndGT4 gene of the landomycin E cluster in S. globisporusBohdan Ostash, Uwe Rix, Lily L Remsing Rix, et al.
FEBS Open Bio|July 18, 2019
Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 modelBhaswati Sarcar, Nicholas T Gimbrone, Gabriela Wright, et al.
Plos One|October 17, 2013
A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALLUwe Rix, Jacques Colinge, Katharina Blatt, et al.
Pageof 9